UY38096A - Inhibidores de arginasa y sus métodos de uso - Google Patents

Inhibidores de arginasa y sus métodos de uso

Info

Publication number
UY38096A
UY38096A UY0001038096A UY38096A UY38096A UY 38096 A UY38096 A UY 38096A UY 0001038096 A UY0001038096 A UY 0001038096A UY 38096 A UY38096 A UY 38096A UY 38096 A UY38096 A UY 38096A
Authority
UY
Uruguay
Prior art keywords
methods
arginase inhibitors
compounds
formula
arginase
Prior art date
Application number
UY0001038096A
Other languages
English (en)
Inventor
Nathan Mlynarski Scott
Tyler Grebe
Sameer Kawatkar
Raymond Verschoyle Finlay Maurice
Iain Simpson
Jianyan Wang
Steve Cook
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY38096A publication Critical patent/UY38096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula (Ia) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ia) y métodos para utilizarlas en el tratamiento del cáncer o una enfermedad respiratoria inflamatoria y la inhibición de la arginasa:
UY0001038096A 2018-02-17 2019-02-15 Inhibidores de arginasa y sus métodos de uso UY38096A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862631659P 2018-02-17 2018-02-17
US201862671576P 2018-05-15 2018-05-15
US201862721113P 2018-08-22 2018-08-22
US201862778002P 2018-12-11 2018-12-11

Publications (1)

Publication Number Publication Date
UY38096A true UY38096A (es) 2019-07-31

Family

ID=65763693

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038096A UY38096A (es) 2018-02-17 2019-02-15 Inhibidores de arginasa y sus métodos de uso

Country Status (22)

Country Link
US (3) US11420984B2 (es)
EP (1) EP3752251A1 (es)
JP (2) JP7317841B2 (es)
KR (1) KR102657919B1 (es)
CN (3) CN111712302B (es)
AU (2) AU2019221896B2 (es)
BR (1) BR112020015973A2 (es)
CA (1) CA3091365A1 (es)
CL (1) CL2020002096A1 (es)
CR (1) CR20200418A (es)
DO (1) DOP2020000145A (es)
EC (1) ECSP20058183A (es)
IL (1) IL276711B2 (es)
JO (1) JOP20200197A1 (es)
MA (1) MA51837A (es)
MX (1) MX2020008570A (es)
NI (1) NI202000055A (es)
PE (1) PE20210176A1 (es)
SG (1) SG11202007739XA (es)
TW (1) TWI803574B (es)
UY (1) UY38096A (es)
WO (1) WO2019159120A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019159120A1 (en) * 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
WO2019186497A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
AU2019323663B2 (en) 2018-08-22 2022-07-14 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4054591A1 (en) 2019-11-04 2022-09-14 Astrazeneca AB Combination therapy for treating cancer
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729936T3 (es) 2010-04-22 2019-11-07 Mars Inc Inhibidores de arginasa y sus aplicaciones terapéuticas
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
CA2824599C (en) 2010-12-31 2020-03-10 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP3368541B1 (en) 2015-10-30 2020-05-27 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
CN110352063A (zh) * 2016-11-08 2019-10-18 卡里塞拉生物科学股份公司 精氨酸酶抑制剂组合疗法
ES2970715T3 (es) 2016-12-22 2024-05-30 Prec Pharmaceuticals Inc Composiciones y métodos para inhibir la actividad de la arginasa
WO2019120296A1 (en) 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
WO2019159120A1 (en) * 2018-02-17 2019-08-22 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
AU2019221896B2 (en) 2022-03-24
DOP2020000145A (es) 2020-09-15
WO2019159120A1 (en) 2019-08-22
TWI803574B (zh) 2023-06-01
KR20200122341A (ko) 2020-10-27
IL276711A (en) 2020-09-30
US20230365599A1 (en) 2023-11-16
JP7317841B2 (ja) 2023-07-31
AU2022203938B2 (en) 2024-02-01
CA3091365A1 (en) 2019-08-22
US20230122859A1 (en) 2023-04-20
JP2023145557A (ja) 2023-10-11
CN117180290A (zh) 2023-12-08
AU2022203938A1 (en) 2022-06-23
BR112020015973A2 (pt) 2020-12-15
KR102657919B1 (ko) 2024-04-15
CN111712302A (zh) 2020-09-25
NZ767738A (en) 2023-12-22
JP2021513964A (ja) 2021-06-03
CL2020002096A1 (es) 2020-12-18
CN111712302B (zh) 2023-09-19
US20210002305A1 (en) 2021-01-07
PE20210176A1 (es) 2021-01-29
TW201945004A (zh) 2019-12-01
JOP20200197A1 (ar) 2020-08-16
NI202000055A (es) 2021-06-22
MA51837A (fr) 2021-06-16
IL276711B2 (en) 2024-06-01
CN117186134A (zh) 2023-12-08
EP3752251A1 (en) 2020-12-23
CR20200418A (es) 2020-10-27
IL276711B1 (en) 2024-02-01
MX2020008570A (es) 2020-09-21
ECSP20058183A (es) 2020-10-30
US11912727B2 (en) 2024-02-27
SG11202007739XA (en) 2020-09-29
US11420984B2 (en) 2022-08-23
AU2019221896A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
PH12016502353A1 (en) Pharmaceutical composition
CO2020004669A2 (es) Derivados de bencimidazol y sus usos
TW201613577A (en) Pharmaceutical combinations
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CR20160527A (es) Derivados de carboxamida
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2016001361A1 (es) Regimen de dosificación para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa